ApoCell, Inc. Awarded $2.9 Million from SAIC-Frederick, Inc. to Deliver a New Platform for Detection and Molecular Analysis of Circulating Tumor Cells (CTCs) to the National Cancer Institute’s Pharmacodynamics Program

Published: Aug 10, 2011

HOUSTON--(BUSINESS WIRE)--ApoCell, Inc. announced the award of a $2.9 million contract from SAIC-Frederick Inc. (SAIC-F), in support of the National Cancer Institute, for the development and delivery of 12 alpha prototype units of the ApoCell DEP-FFF circulating tumor cell (CTC) detection system, called ApoStream™. The project, funded by the American Recovery and Reinvestment Act (ARRA), is for the delivery of technology for CTC capture and analysis to determine the effects of targeted cancer therapies.

Back to news